{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T09:10:35Z","timestamp":1722330635830},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s10067-012-2072-7","type":"journal-article","created":{"date-parts":[[2012,8,31]],"date-time":"2012-08-31T10:42:29Z","timestamp":1346409749000},"page":"1677-1682","source":"Crossref","is-referenced-by-count":9,"title":["Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept"],"prefix":"10.1007","volume":"31","author":[{"given":"J. C.","family":"van Denderen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. J.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. E.","family":"van der Horst-Bruinsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. A. C.","family":"Dijkmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,1]]},"reference":[{"key":"2072_CR1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","volume":"65","author":"J Zochling","year":"2006","unstructured":"Zochling J, Van der Heyde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B et al (2006) ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442\u2013452","journal-title":"Ann Rheum Dis"},{"key":"2072_CR2","unstructured":"European Medicines Agency: EPAR product information etanercept (2012) http:\/\/www.emea.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000262\/human_med_000764.jsp&mid=WC0b01ac058001d124 . Accessed Aug 2012"},{"key":"2072_CR3","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346:1349\u20131356","journal-title":"N Engl J Med"},{"key":"2072_CR4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5694\/j.1326-5377.2007.tb01396.x","volume":"187","author":"G Ozorio","year":"2007","unstructured":"Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C (2007) Autoimmune hepatitis. following infliximab therapy for ankylosing spondylitis. Med J Aust 187:524\u2013526","journal-title":"Med J Aust"},{"key":"2072_CR5","first-page":"349","volume":"35","author":"M Farah","year":"2008","unstructured":"Farah M, Al Rashidi A, Owen DA, Yoshida EM, Reid GD (2008) Granulomatous hepatitis associated with etanercept therapy. J Rheumatol 35:349\u2013351","journal-title":"J Rheumatol"},{"key":"2072_CR6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10067-009-1179-y","volume":"28","author":"KM Carlsen","year":"2009","unstructured":"Carlsen KM, Riis L, Madsen OR (2009) Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 28:1001\u20131003","journal-title":"Clin Rheumatol"},{"key":"2072_CR7","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","volume":"26","author":"GJ Tobon","year":"2007","unstructured":"Tobon GJ, Ca\u00f1as C, Jaller JJ, Restrepo JC, Anaya JM (2007) Serious liver disease induced by infliximab. Clin Rheumatol 26:578\u2013581","journal-title":"Clin Rheumatol"},{"key":"2072_CR8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","volume":"62","author":"J Braun","year":"2003","unstructured":"Braun J, Pham T, Sieper J, Davis J, Van der Linden S, Dougados M et al (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817\u2013824","journal-title":"Ann Rheum Dis"},{"key":"2072_CR9","unstructured":"The Uppsala Monitoring Centre: The use of the WHO-UMC system for standardised care causality assessment, undated. http:\/\/who-umc.org\/Graphics\/24734.pdf . Accessed Aug 2012"},{"key":"2072_CR10","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.21171","volume":"43","author":"GN Ioannou","year":"2006","unstructured":"Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP (2006) Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 43:1145\u20131151","journal-title":"Hepatology"},{"key":"2072_CR11","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"63","author":"A Calin","year":"2004","unstructured":"Calin A, Dijkmans BAC, Emery P, Hakala M, Kalden J, Leirisalo-Repo M et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594\u20131600","journal-title":"Ann Rheum Dis"},{"key":"2072_CR12","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","volume":"65","author":"D Heijde Van der","year":"2006","unstructured":"Van der Heijde D, Da Silva JC, Dougados M, Geher P, Van der Horst-Bruinsma IE, Juanola X et al (2006) Etanercept 50\u00a0mg once weekly is as effective as 25\u00a0mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65:1572\u20131577","journal-title":"Ann Rheum Dis"},{"key":"2072_CR13","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde Van der","year":"2006","unstructured":"Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136\u20132146","journal-title":"Arthritis Rheum"},{"key":"2072_CR14","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Van der Heijde D, Diekman L, Sieper J, Kim SI et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58:3402\u20133412","journal-title":"Arthritis Rheum"},{"key":"2072_CR15","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/ard.2009.112136","volume":"69","author":"J Sokolove","year":"2010","unstructured":"Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM et al (2010) Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 69:1612\u20131617","journal-title":"Ann Rheum Dis"},{"key":"2072_CR16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/039463200902200234","volume":"22","author":"M Massarotti","year":"2009","unstructured":"Massarotti M, Marasini B (2009) Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol 22:547\u2013549","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2072_CR17","unstructured":"European Medicines Agency: EPAR product information infliximab (2012) http:\/\/www.emea.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000240\/human_med_001023.jsp&mid=WC0b01ac058001d124 ; table 2. Accessed Aug 2012"},{"key":"2072_CR18","first-page":"421","volume":"35","author":"DU Cansu","year":"2008","unstructured":"Cansu DU, Kalifoglu T, Korkmaz C (2008) Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 35:421\u2013424","journal-title":"J Rheumatol"},{"key":"2072_CR19","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","volume":"62","author":"JR Peterson","year":"2003","unstructured":"Peterson JR, Hsu FC, Simkin PA, Wener MH (2003) Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62:1078\u20131082","journal-title":"Ann Rheum Dis"},{"key":"2072_CR20","first-page":"107","volume":"31","author":"O Oniankitan","year":"2004","unstructured":"Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM et al (2004) Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31:107\u2013109","journal-title":"J Rheumatol"},{"key":"2072_CR21","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.20702","volume":"51","author":"FA Parke","year":"2004","unstructured":"Parke FA, Reveille JD (2004) Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51:800\u2013804","journal-title":"Arthritis Rheum"},{"key":"2072_CR22","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/kel123","volume":"45","author":"CH Roux","year":"2006","unstructured":"Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2006) Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 45:1294\u20131297","journal-title":"Rheumatology"},{"key":"2072_CR23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/rheumatology\/kel191","volume":"46","author":"H Marotte","year":"2007","unstructured":"Marotte H, Fontanges E, Bailly F, Zoulim F, Trepo C, Miossec P (2007) Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology 46:97\u201399","journal-title":"Rheumatology"},{"key":"2072_CR24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/rheumatology\/kep046","volume":"48","author":"CI Da\u00efen","year":"2009","unstructured":"Da\u00efen CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E et al (2009) Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology 48:883\u2013886","journal-title":"Rheumatology"},{"key":"2072_CR25","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Br\u00e9ban M et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 60:1884\u20131894","journal-title":"Arthritis Rheum"},{"key":"2072_CR26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4065\/76.1.84","volume":"76","author":"VV Menghini","year":"2001","unstructured":"Menghini VV, Arora AS (2001) Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 76:84\u201386","journal-title":"Mayo Clin Proc"},{"key":"2072_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","volume":"137","author":"D Prati","year":"2002","unstructured":"Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E et al (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137:1\u201310","journal-title":"Ann Intern Med"},{"key":"2072_CR28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","volume":"44","author":"M Ekstedt","year":"2006","unstructured":"Ekstedt M, Franz\u00e9n LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G et al (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865\u2013873","journal-title":"Hepatology"},{"key":"2072_CR29","first-page":"2099","volume":"54","author":"CJ Chu","year":"2007","unstructured":"Chu CJ, Lu RH, Wang SS, Chang FY, Wu SL, Lu CL et al (2007) Risk factors associated with non-alcoholic fatty liver disease in Chinese patients and the role of tumor necrosis factor-alpha. Hepatogastroenterology 54:2099\u20132102","journal-title":"Hepatogastroenterology"},{"key":"2072_CR30","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1136\/ard.2009.127597","volume":"69","author":"A Jamnitski","year":"2010","unstructured":"Jamnitski A, Visman IM, Peters MJ, Dijkmans BA, Voskuyl AE, Nurmohamed MT (2010) Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis 69:1929\u20131933","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-012-2072-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-012-2072-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-012-2072-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T02:25:59Z","timestamp":1594607159000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-012-2072-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,1]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2072"],"URL":"https:\/\/doi.org\/10.1007\/s10067-012-2072-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,1]]}}}